Carles Rafols Priu

Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

V. Barrios, M. A. Esteve-Pastor, G. Barón-Esquivias, 2022, Cardiology journal.

Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.

J. Masjuán, V. Barrios, G. Barón-Esquivias, 2022, Journal of comparative effectiveness research.

Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

J. Masjuán, V. Barrios, G. Barón-Esquivias, 2022, Cardiology journal.

Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.

J. Masjuán, V. Barrios, J. Rivera‐Caravaca, 2022, European Heart Journal - Cardiovascular Pharmacotherapy.

Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.

J. Masjuán, V. Barrios, G. Barón-Esquivias, 2023, Journal of comparative effectiveness research.